Core Laboratories will hold its Q3 2026 earnings conference call on October 29, 2026, to discuss financial and operational results. The earnings press release will be published after market close on October 28 and available on the company's website. Investors and analysts can join a live webcast or access a replay and transcript afterward. Core Laboratories provides specialized services to optimize petroleum reservoir performance globally.
Core Laboratories' upcoming Q3 2026 earnings release and conference call provide context for energy sector activity. For readers following the energy sector, here is Pluang's market snapshot as of Oct 02, 2026 03:26 WIB: Among 38 priced US energy stocks, 21 rose and 17 fell. Valero Energy Corporation (VLO) led gains with a 5.35% increase to USD 408.35, contrasting with Occidental Petroleum Corporation (OXY) which rose 4.52% to USD 57.82 and Enphase Energy Inc (ENPH) up 3.68% at USD 33.00. Typical hold times on Pluang ranged from 56 to 91 days, with VLO showing a strong sell bias at 79% sell orders, while OXY had 100% buy orders.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
